Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth

Dupilumab (Dupixent) continues strong growth with €10.7 billion in 2023 sales and $4.34 billion in Q2 2025. FDA approval for COPD in September 2024 and expansion to chronic spontaneous urticaria in children unlock new market opportunities. The drug demonstrates clinical superiority over competitors like Xolair, with market projections extending to 2034 across multiple indications and geographic regions.

07/03/2026, 4:40 AM • GlobeNewswire

Communiqué de presse : Mise en ligne du document «Q2 2026 aide-mémoire »

Sanofi has published its Q2 2026 financial aide-mémoire to assist with quarterly financial modeling, with full Q2 2026 results scheduled for July 30, 2026. Additionally, Sanofi's Nexviazyme met all primary and secondary endpoints in a phase 3 study for infantile-onset Pompe disease, representing a significant clinical achievement for the company's pipeline.

07/01/2026, 1:30 AM • GlobeNewswire

Press Release: Availability of the aide-mémoire for Q2 2026 results

Sanofi announced the availability of its aide-mémoire for Q2 2026 results on July 1, 2026, to support financial modeling of quarterly results. The document covers non-comparable items, foreign currency impact, and share count. Full Q2 2026 results will be published on July 30, 2026.

07/01/2026, 1:30 AM • GlobeNewswire

Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows

Three high-yielding dividend stocks that recently hit 52-week lows are presented as potential bargain opportunities: Sanofi (5.7% yield) despite patent expiration concerns, AT&T (5.3% yield) facing Starlink competition worries, and Vici Properties (6.7% yield) offering stable dividend income. All three trade at attractive valuations with strong dividend coverage.

06/30/2026, 3:04 PM • The Motley Fool

Press Release: Sanofi Foundation opens new chapter centered on future generations

The Sanofi Foundation announced a strengthened commitment to children and young people facing serious diseases, climate, and humanitarian challenges. The foundation will allocate €15 million annually for programs benefiting children and youth, with partnerships including the Cerebral Palsy Foundation and AIDA. The foundation aims to impact over 6 million children and young people by 2030, while continuing humanitarian efforts that have reached 26 million patients across 45 countries.

06/25/2026, 2:00 AM • GlobeNewswire

Communiqué de presse : La Fondation Sanofi ouvre un nouveau chapitre centré sur les générations futures

The Sanofi Foundation announced a strengthened commitment to children and young people facing serious illnesses, climate challenges, and humanitarian crises. With an annual budget of €15 million, the foundation aims to impact over 6 million children and youth by 2030 through partnerships addressing early diagnosis, mental health support, and disease elimination efforts.

06/25/2026, 2:00 AM • GlobeNewswire

Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia

Sanofi announced that its drug Wayrilz (rilzabrutinib), a BTK inhibitor, has received marketing authorization in Japan for treating persistent or chronic immune thrombocytopenia (ITP) in patients who don't respond to other treatments. The approval is based on the LUNA 3 phase 3 study, which demonstrated rapid and durable platelet response and improved quality of life compared to placebo.

06/23/2026, 1:15 AM • GlobeNewswire

Communiqué de presse : Wayrilz de Sanofi a été approuvé au Japon pour traiter la thrombocytopénie immunitaire

Sanofi announced that Wayrilz (rilzabrutinib), a BTK inhibitor, has received regulatory approval in Japan for treating persistent or chronic immune thrombocytopenia (ITP) in patients who are inadequately responsive to other treatments. The approval is based on the Phase 3 LUNA 3 trial, which demonstrated rapid and sustained platelet response and improved quality of life metrics. Wayrilz is now approved in the US, EU, UAE, UK, and Japan.

06/23/2026, 1:15 AM • GlobeNewswire

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

The European Commission has approved Sanofi's Cenrifki (tolebrutinib) for treating secondary progressive multiple sclerosis without relapses, marking the first disability-targeting therapy for this condition. The approval is based on the HERCULES phase 3 study demonstrating significant delay in disability progression. However, the drug carries identified safety risks including drug-induced liver injury, requiring strict liver monitoring.

06/23/2026, 1:00 AM • GlobeNewswire

Communiqué de presse : Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes

The European Commission has approved Sanofi's Cenrifki (tolebrutinib), a brain-penetrating Bruton tyrosine kinase inhibitor, for treating secondary progressive multiple sclerosis (SPMS) without relapses. The approval is based on the Phase 3 HERCULES trial, which demonstrated that Cenrifki significantly delayed disability progression. The drug will be commercially available in Germany this year, with careful risk management protocols due to identified hepatic safety concerns.

06/23/2026, 1:00 AM • GlobeNewswire

Communiqué de presse : Sarclisa de Sanofi en formulation sous-cutanée approuvé au Japon pour les patients atteints de myélome multiple

Sanofi a obtenu l'approbation au Japon pour Sarclisa en formulation sous-cutanée (SC) pour traiter le myélome multiple. Il s'agit de la deuxième approbation mondiale après l'UE. L'étude pivot IRAKLIA a démontré l'efficacité non-inférieure de la formulation SC par rapport à la formulation intraveineuse, avec un taux de réponse objective de 71,1% et un profil de sécurité amélioré.

06/19/2026, 6:31 AM • GlobeNewswire

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi announced approval of Sarclisa (isatuximab) subcutaneous formulation in Japan for multiple myeloma treatment in combination with standard-of-care regimens. This is the second global approval following EU authorization. The approval is based on the IRAKLIA phase 3 study demonstrating non-inferior efficacy and pharmacokinetics compared to intravenous formulation, with significantly fewer infusion reactions (1.5% vs 25%).

06/19/2026, 6:31 AM • GlobeNewswire

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.

06/18/2026, 1:00 PM • GlobeNewswire

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire